Overcoming Challenges in Treating MCL
Jonathon B. Cohen, MD, discusses the biggest challenge in treating mantle cell lymphoma and how these challenges can be overcome.
Jonathon B. Cohen, MD, assistant professor, department of hematology and medical oncology, Winship Cancer Institute, Emory University School of Medicine, discusses the biggest challenge in treating mantle cell lymphoma (MCL) and how these challenges can be overcome.
The real challenge with MCL is that it is a rare disease that can present with very different types of behaviors, Cohen says. A physician may only see 1 of these patients once or twice a year, and all of these patients will present different clinical behavior.
This has made treating patients with MCL a challenge. In the past, Cohen says if a patient could receive intensive therapy, they were given that treatment. If they were not able to receive it, they didn’t. In some cases it worked while in others it didn’t.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
